According to this recent study (soon to be published in JAMA), antithrombotic therapy has no clinical benefits for outpatients with stable symptoms of COVID-19. Both aspirin and apixaban in therapeutic or prophylactic doses did not reduce major cardiovascular events compared against placebo, though these events are rare, which makes it difficult to show any benefit. …
Hypertensive Patients: Maximizing Doses or Adding New Drugs
Adding new medication in moderate doses to control hypertension conveniently maximizes efficacy, reduces adverse effects and minimizes costs, among other advantages. On the flipside, patients having to remember a whole list of drugs and their combination will often lead to non-adherence or forgetfulness. The latter has been shown not only by dedicated trials, but also…
STOPDAPT-2 ACS: One-Month DAPT NOT Enough in acute patients
One-month dual antiplatelet therapy (DAPT) in patients undergoing acute coronary syndrome (ACS) did not reach the safety and efficacy results observed in the general population of the original trial STOPDAPT-2. The STOPDAPT-2 ACS compared one-month DAPT followed by clopidogrel monotherapy for one year vs. one-year DAPT after PCI. Initially, the study enrolled mostly stable patients…
TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors?
In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors. Cardiologists, hematologists, clinicians, and…
XIENCE SHORT DAPT | Ideal DAPT Period for Patients at High Risk of Bleeding
In patients at high risk of bleeding undergoing coronary stenting with a Xience stent, 1-to-3-month DAPT period resulted non-inferior to a 6-to-12-month period in terms of ischemic events, and this could be associated to a lower rate of major bleeding and lower stent thrombosis incidence. There is no longer an indication for conventional stents in…
Thrombotic and Bleeding Risk after TAVR: Quick Tips to Stay Up to Date
Transcatheter aortic valve replacement (TAVR) is an increasingly frequent option for patients with severe aortic stenosis across the entire risk spectrum. However, TAVR involves bleeding and thrombosis risk and therefore calls for an optimal adjuvant treatment. Any scheme is complex if we take into account most patients undergoing TAVR are generally elderly and have multiple…
SOLACI-CACI 2021 | DAPT Session
✔️ Watch again the DAPT Session in the SOLACI-CACI 2021 Congress. 👨🏫 Program: 02:58 – Short versus long-term DAPT Therapy in High Risk Bleeding. Rationality and Preliminary Results of Master DAPT trial – Peter Smits. 31:20 – Rationality of long-term DAPT in Chronic Stable Angina – Ernesto Duronto. 48:14 – Selection of the best P2Y12…
SOLACI-CACI 2021 | SCAI Session
✔️ SCAI Session (Society for Cardiovascular Angiography and Interventions) in the SOLACI-CACI 2021 Congress. 👨🏫 Program: 00:03 – STEMI: Approach to Left Main Culprit – Dr. Timothy Henry. 15:38 – Gender Disparities in STEMI – Dr. Cindy Grines. 29:52 – Optimal DAPT Post Complex PCI – Dr. George Dangas. 47:01 – PCI or CABG for…
SOLACI-CACI 2021 | SAC-FAC Session
✔️ Watch again the complete SAC-FAC Session in the SOLACI-CACI 2021 Congress. 👨🏫 Program: – SESSION I: Functional Mitral Regurgitation: New Horizons for Transcatheter Therapy 01:06 – Optimal Medical Treatment in Patients with Cardiac Failure and Mitral Regurgitation – Florencia Renedo 12:12 – Ultrasonographic Screening of Patients for Endovascular Therapy – Walter García 25:43 –…
Can Ticagrelor Prevent Strokes in High-Risk Patients?
In addition to aspirin, Ticagrelor offers better prognosis in patients that already had a stroke and have a high-risk cardiovascular profile. These benefits should be correctly balanced seeing as they are not free of risk. Antiplatelet therapy makes part of the standard treatment of cardiac or cerebrovascular patients. Ticagrelor has shown superior to clopidogrel in…
ESC 2021 | ENVISAGE-TAVI AF: Surprise with Endoxaban in TAVR and Atrial Fibrillation
The enthusiasm for direct oral anticoagulants after transcatheter aortic valve replacements (TAVR) is waning. At least, when it combines with atrial fibrillation. The ENVISAGE-TAVI AF has shown excessive bleeding with endoxaban vs. the classical vitamin K antagonists. Endoxaban resulted non-inferior to vitamin K antagonists in terms of net clinical adverse events, but major bleeding events…